192 related articles for article (PubMed ID: 24671426)
1. MAGE-A3 with cell-penetrating domain as an efficient therapeutic cancer vaccine.
Batchu RB; Gruzdyn O; Potti RB; Weaver DW; Gruber SA
JAMA Surg; 2014 May; 149(5):451-7. PubMed ID: 24671426
[TBL] [Abstract][Full Text] [Related]
2. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K
Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399
[TBL] [Abstract][Full Text] [Related]
3. Enhanced intracellular targeting of tumor-specific antigens: you can lead a horse to water, but….
Berger DH
JAMA Surg; 2014 May; 149(5):457-8. PubMed ID: 24671363
[No Abstract] [Full Text] [Related]
4. Efficient induction of anti-tumor immune response in esophageal squamous cell carcinoma via dendritic cells expressing MAGE-A3 and CALR antigens.
Liu X; Song N; Liu Y; Liu Y; Li J; Ding J; Tong Z
Cell Immunol; 2015 Jun; 295(2):77-82. PubMed ID: 25863743
[TBL] [Abstract][Full Text] [Related]
5. Calreticulin acts as an adjuvant to promote dendritic cell maturation and enhances antigen-specific cytotoxic T lymphocyte responses against non-small cell lung cancer cells.
Liu X; Li J; Liu Y; Ding J; Tong Z; Liu Y; Zhou Y; Liu Y
Cell Immunol; 2016 Feb; 300():46-53. PubMed ID: 26702740
[TBL] [Abstract][Full Text] [Related]
6. Induction of antigen-specific immune responses by dendritic cells transduced with a recombinant lentiviral vector encoding MAGE-A3 gene.
Lin L; Wei J; Chen Y; Huang A; Li KK; Zhang W
J Cancer Res Clin Oncol; 2014 Feb; 140(2):281-9. PubMed ID: 24322180
[TBL] [Abstract][Full Text] [Related]
7. Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma.
Szmania S; Gnjatic S; Tricot G; Stone K; Zhan F; Moreno A; Thuro B; Melenhorst J; Barrett J; Shaughnessy J; Old LJ; Barlogie B; Brichard VG; van Rhee F
J Immunother; 2007; 30(8):847-54. PubMed ID: 18049337
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide.
Nishiyama T; Tachibana M; Horiguchi Y; Nakamura K; Ikeda Y; Takesako K; Murai M
Clin Cancer Res; 2001 Jan; 7(1):23-31. PubMed ID: 11205913
[TBL] [Abstract][Full Text] [Related]
9. Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients.
Bonehill A; Van Nuffel AM; Corthals J; Tuyaerts S; Heirman C; François V; Colau D; van der Bruggen P; Neyns B; Thielemans K
Clin Cancer Res; 2009 May; 15(10):3366-75. PubMed ID: 19417017
[TBL] [Abstract][Full Text] [Related]
10. Efficient lysis of epithelial ovarian cancer cells by MAGE-A3-induced cytotoxic T lymphocytes using rAAV-6 capsid mutant vector.
Batchu RB; Gruzdyn OV; Moreno-Bost AM; Szmania S; Jayandharan G; Srivastava A; Kolli BK; Weaver DW; van Rhee F; Gruber SA
Vaccine; 2014 Feb; 32(8):938-43. PubMed ID: 24406390
[TBL] [Abstract][Full Text] [Related]
11. Transient expansion of peptide-specific lymphocytes producing IFN-gamma after vaccination with dendritic cells pulsed with MAGE peptides in patients with mage-A1/A3-positive tumors.
Toungouz M; Libin M; Bulté F; Faid L; Lehmann F; Duriau D; Laporte M; Gangji D; Bruyns C; Lambermont M; Goldman M; Velu T
J Leukoc Biol; 2001 Jun; 69(6):937-43. PubMed ID: 11404379
[TBL] [Abstract][Full Text] [Related]
12. Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles.
Kobayashi H; Song Y; Hoon DS; Appella E; Celis E
Cancer Res; 2001 Jun; 61(12):4773-8. PubMed ID: 11406551
[TBL] [Abstract][Full Text] [Related]
13. A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes.
Schultz ES; Lethé B; Cambiaso CL; Van Snick J; Chaux P; Corthals J; Heirman C; Thielemans K; Boon T; van der Bruggen P
Cancer Res; 2000 Nov; 60(22):6272-5. PubMed ID: 11103782
[TBL] [Abstract][Full Text] [Related]
14. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
[TBL] [Abstract][Full Text] [Related]
15. MAGE-A3: an immunogenic target used in clinical practice.
Esfandiary A; Ghafouri-Fard S
Immunotherapy; 2015; 7(6):683-704. PubMed ID: 26100270
[TBL] [Abstract][Full Text] [Related]
16. Induction of Humoral and Cellular Immune Responses in Mice by Multiepitope Vaccines Composing of Both T and B Lymphocyte Epitopes of MAGE-A3 which are Recombined into HBcAg.
Chen Q; Li W; Wang P; Shao H; Ding Y; Wang W; Cen D; Cai Y; Xue X; Zhang L; Zhu G
Protein Pept Lett; 2017; 24(10):947-954. PubMed ID: 28641561
[TBL] [Abstract][Full Text] [Related]
17. Human dendritic cells engineered to secrete interleukin-18 activate MAGE-A3-specific cytotoxic T lymphocytes in vitro.
Fan X; Ye M; Xue B; Ke Y; Wong CK; Xie Y
Immunol Invest; 2012; 41(5):469-83. PubMed ID: 22490235
[TBL] [Abstract][Full Text] [Related]
18. The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells.
François V; Ottaviani S; Renkvist N; Stockis J; Schuler G; Thielemans K; Colau D; Marchand M; Boon T; Lucas S; van der Bruggen P
Cancer Res; 2009 May; 69(10):4335-45. PubMed ID: 19435913
[TBL] [Abstract][Full Text] [Related]
19. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma.
Kruit WH; Suciu S; Dreno B; Mortier L; Robert C; Chiarion-Sileni V; Maio M; Testori A; Dorval T; Grob JJ; Becker JC; Spatz A; Eggermont AM; Louahed J; Lehmann FF; Brichard VG; Keilholz U
J Clin Oncol; 2013 Jul; 31(19):2413-20. PubMed ID: 23715572
[TBL] [Abstract][Full Text] [Related]
20. Lysis of human chondrosarcoma cells by cytolytic T lymphocytes recognizing a MAGE-A3 antigen presented by HLA-A1 molecules.
Bluman EM; Coulie PG; Xiaojuan S; Machan J; Lin C; Meitner PA; Block JA; Terek RM
J Orthop Res; 2007 May; 25(5):678-84. PubMed ID: 17290408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
